A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib

Documenti analoghi

• Sexually dimorphic effects of pexidartinib on nerve injury‐induced neuropathic pain in mice
  di: Fumihiro Saika, et al.
  Pubblicazione: (2024)
• BRAF/MEK inhibitor rechallenge in advanced melanoma patients
  di: Olivier J. Van Not, et al.
  Pubblicazione: (2024)
• The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action
  di: Stephan C. Tap
  Pubblicazione: (2024)
• Real‐World Experience Using Brigimadlin (MDM2 Inhibitor) in an Australian Sarcoma Specialist Center Compared to Pivotal Clinical Trial Results
  di: Karan Gupta, et al.
  Pubblicazione: (2025)
• A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
  di: Matthew Youssef, et al.
  Pubblicazione: (2026)